Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 6
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Holtz, Nathan A. Tedford, Stephanie E. Persons, Amanda L. Grasso, Salvatore A. and Napier, T. Celeste 2016. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 70, p. 77.

    Um, Yoo Hyun Kim, Tae-Won Jeong, Jong-Hyun Seo, Ho-Jun Han, Jin-Hee Hong, Seung-Chul Jung, Won-Sang Choi, Woo Hee Lee, Chang-Uk and Lim, Hyun Kook 2016. Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report. Psychiatry Investigation, Vol. 13, Issue. 3, p. 364.

    Huot, Philippe Fox, Susan H. and Brotchie, Jonathan M. 2015. Monoamine Reuptake Inhibitors in Parkinson’s Disease. Parkinson's Disease, Vol. 2015, p. 1.

    Broadstock, Martin Ballard, Clive and Corbett, Anne 2014. Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease. Expert Review of Clinical Pharmacology, Vol. 7, Issue. 6, p. 779.

    Huynh, Niem Tu and Huot, Philippe 2014. Therapies under investigation for treating Parkinson's disease psychosis. Clinical Investigation, Vol. 4, Issue. 10, p. 889.

    2014. Levodopa/quetiapine. Reactions Weekly, Vol. 1521, Issue. 1, p. 107.


A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease

  • Tomoyuki Nagata (a1), Shunichiro Shinagawa (a1), Kenji Tagai (a1) and Kazuhiko Nakayama (a1)
  • DOI:
  • Published online: 30 November 2012

A 48-year-old woman with Parkinson disease (PD) suffered from auditory hallucinations (AH). We had treated her with a reduction in antiparkinsonian agents and the use of atypical antipsychotic agents. However, her symptoms did not improve, and her extrapyramidal symptoms (EPS) worsened. To lessen her depressive symptoms, treatment with a new-generation antidepressant, mirtazapine (MRZ), was commenced. The patient's AH gradually decreased with no worsening of EPS, and the AH disappeared 4 weeks after the commencement of treatment with MRZ. The present case suggests the effectiveness of MRZ for the treatment of refractory AHs in patients with PD.

Corresponding author
Correspondence should be addressed to: Tomoyuki Nagata, Department of Psychiatry, Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. Phone: +81 334 331 111; Fax: +81 334 370 228. Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

G. Fénelon (2008). Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectrums, 13, 1825.

R. Inzelberg , S. Kipervasser and A. D. Korczyn (1998). Auditory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 64, 533535.

G. Meco and S. Bernardi (2007). Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31, 311313.

C. Normann et al. (1997). Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry, 30, 263265.

B. Ravina et al. (2007). Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders, 22, 10611068.

L. B. Zahodne and Fernandez, H. H. (2008). Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs and Aging, 25, 665682.

J. Zoldan , G. Friedberg , M. Livneh and E. Melamed (1995). Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology, 45, 13051308.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *